Corey A. Siegel, MD
Therapeutic drug monitoring (TDM) has been shown to help physicians treat patients with inflammatory bowel disease who take anti–tumor necrosis factor drugs. One group has committed itself to making TDM easier and more accessible to gastroenterologists and experts in IBD. BridgeIBD, a group of 13 gastroenterologists from four countries, was established in 2005 in order to integrate TDM into GI practices. Since its inception, the group has met annually to tackle new